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Abstract 
The inhibitory γ-aminobutyric acid (GABA) neurotransmitter system is associated 
with the regulation of normal cognitive functions and dysregulation has been 
reported in a number of neuropsychiatric disorders including anxiety disorders, 
schizophrenia and addictions. Investigating the role of GABA in both health and 
disease has been constrained by difficulties in measuring acute changes in synaptic 
GABA using neurochemical imaging. The aim of this study was to investigate 
whether acute increases in synaptic GABA are detectable in the living human brain 
using the inverse agonist GABA-benzodiazepine receptor (GABA-BZR) positron 
emission tomography (PET) tracer, [11C]Ro15-4513. We examined the effect of 
15mg oral tiagabine, which increases synaptic GABA by inhibiting the GAT1 GABA 
uptake transporter, on [11C]Ro15-4513 binding in 12 male participants using a 
paired, double blind, placebo-controlled protocol. Spectral analysis was used to 
examine synaptic α1 and extrasynaptic α5 GABA-BZR subtype availability in brain 
regions with high levels of [11C]Ro15-4513 binding. We also examined the test-retest 
reliability of α1 and a5-specific [11C]Ro15-4513 binding in a separate cohort of 4 
participants using the same spectral analysis protocol. Tiagabine administration 
produced significant reductions in hippocampal, parahippocampal, amygdala and 
anterior cingulate synaptic α1 [11C]Ro15-4513 binding, and a trend significance 
reduction in the nucleus accumbens. These reductions were greater than test-retest 
reliability, indicating that they are not the result of chance observations. Our results 
suggest that acute increases in endogenous synaptic GABA are detectable in the 
living human brain using [11C]Ro15-4513 PET. These findings have potentially major 
implications for the investigation of GABA function in brain disorders and in the 
development of new treatments targeting this neurotransmitter system. 
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Introduction 
 
Gamma-aminobutyric acid (GABA) is the most important and ubiquitous inhibitory 
neurotransmitter in the brain. The GABA system is associated with a number of 
important cognitive functions including memory (Michels et al., 2012), attention 
(Smolnik et al., 1998) and associative learning (Makkar et al., 2010). Dysregulation 
within the GABA system has been reported in many neuropsychiatric disorders, such 
as anxiety and panic disorders (Malizia et al., 1998), epilepsy (Baulac et al., 2001; 
Loup et al., 2000), schizophrenia (Ahn et al., 2011; Hoftman et al., 2013), and 
addiction (Lingford-Hughes et al., 2012). The ability to image synaptic GABA levels 
in the living human brain is therefore critical for our understanding of the role of the 
GABA system in both health and disease.  
 
Currently, human GABA in vivo neuroimaging research predominantly uses positron 
emission tomography (PET) to quantify GABA-benzodiazepine receptor (GABA-
BZR) availability and magnetic resonance spectroscopy (MRS) to index overall 
GABA levels. However, GABA MRS has a number of limitations such as difficulties 
isolating GABA in the spectrum, the need to sample very large voxels, and difficulties 
in interpreting how much of the MRS signal originates from the neurotransmitter or 
synaptic pool compared with the larger metabolic pool. Thus, although MRS studies 
report differences in GABA levels in clinical populations, such as in unipolar 
depression (Sanacora et al., 1999) or after anticonvulsant treatment in epilepsy 
(Doelken et al., 2010), it is impossible to say whether these differences are 
neurotransmitter or metabolic in origin. In addition, the sensitivity of GABA MRS to 
measure expected acute changes in synaptic GABA levels after a pharmacological 
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challenge is inconsistent (Henry et al., 2010; Kupers et al., 2009; Valentine et al., 
2011). In contrast, PET offers a unique opportunity to assess dynamic changes in 
synaptic GABA levels.   
 
Two PET ligands, [11C]flumazenil and [11C]Ro15-4513, are mainly used for in vivo 
neurochemical imaging of the human GABA system and both bind to the 
benzodiazepine site on the GABA-A receptor. GABA-benzodiazepine receptors 
(GABA-BZR’s) contain two subunits from one of six α subunits (α1-α6); GABA-BZR’s 
containing α1-α3 subunits are located intra-synaptically and those containing α4-α6 
are predominantly or exclusively located extra-synaptically (Brunig et al., 2002; 
Kasugai et al., 2010). Measurement of synaptic GABA levels using PET is therefore 
theoretically dependent on the ability to isolate a specific synaptic α1-α3 signal. 
[11C]Flumazenil, the more commonly used radioligand, binds with similar affinity to 
α1-α3 and α5 subtypes and also with somewhat lower affinity to α4 and α6 subtypes 
(Hadingham et al., 1993). It is not therefore currently possible to isolate a specific 
synaptic GABA-BZR PET signal using [11C]flumazenil. Although [11C]Ro15-4513 is 
more selective for the α5 subtype, there is also measurable in vivo binding at the α1 
subtype (Hadingham et al., 1993). We have recently shown that a specific α1 
subtype signal can be quantified in [11C]Ro15-4513 PET studies, by partitioning fast 
and slow ligand kinetics using spectral analysis (Myers et al., 2012).  
 
The pharmacological properties of Ro15-4513 also offer further advantages over 
flumazenil. Ro15-4513 is an inverse GABA-BZR agonist whereas flumazenil is 
generally considered to be an antagonist. The affinity of benzodiazepine full agonists 
or partial agonists, but not antagonists, at the GABA-BZR can alter as a result of 
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changes in synaptic GABA levels – the so called GABA shift (Braestrup et al., 1982; 
Tallman et al., 1978). Consistent with the GABA shift is evidence from 
autoradiographic studies of the primate and rat brain demonstrating that [11C]Ro15-
4513 and [3H]Ro15-4513 binding respectively is markedly reduced by increased 
GABA levels while [11C]flumazenil binding is little affected (Onoe et al., 1996; Tyacke 
et al., 2009). However, whilst flumazenil shows no GABA shift in vitro (Braestrup et 
al., 1982), in some circumstances in vivo it appears to behave as a partial agonist 
(Higgitt et al., 1986; Miller et al., 1988) with a positive shift. This may explain the 
increased binding of [11C]flumazenil in recent human PET studies (Frankle et al., 
2012; Frankle et al., 2009).  
 
The aim of this present study was to determine whether a reduction in synaptic α1-
subtype GABA-BZR affinity produced by increases in synaptic GABA levels could be 
detected in the living human brain. We used tiagabine, which increases synaptic 
GABA levels by selectively inhibiting the GABA transporter 1 (GAT1) in experimental 
animal studies (Fink-Jensen et al., 1992; Richards and Bowery, 1996; Sybirska et 
al., 1993) and in a human case report (During et al., 1992). Tiagabine also produces 
physiological changes consistent with increased GABA concentrations in recent 
MEG studies (Muthukumaraswamy et al., 2013; Muthukumaraswamy et al., 2012). 
Our hypothesis was that tiagabine administration would increase synaptic GABA 
levels and hence reduce the affinity and binding of [11C]Ro15-4513 in brain regions 
with the highest levels of [11C]Ro15-4513 binding where the identification and 
quantification of α1 and α5 binding is most robust and reliable. To examine the 
extent to which these findings differed from chance-level observations, we also 
sought to compare the magnitude of change detected after a tiagabine challenge to 
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the test–retest reliability of α1 and α5-subtype [11C]Ro15-4513 binding in identical 
regions of interest in a separate cohort of participants. 
Paul Stokes et al.  
9 
 
Material and methods 
 
Participants 
Twelve healthy male participants (mean age 50.1 years ± SD: 7.1; 6 non-cigarette 
smokers, 5 ex-cigarette smokers, 1 participant with unknown smoking status) 
completed the tiagabine challenge study, and four healthy male participants (mean 
age 41.5 years ±SD: 4.4; 3 non-smokers, 1 participant with unknown smoking status) 
completed the test-retest reliability study. Exclusion criteria for all participants 
included current or previous significant mental health disorders, alcohol or 
recreational drug dependency as defined by DSM-IV, serious physical illness, past 
neurological disorders, and previous use of psychotropic medications. Potential 
participants underwent urine drug screening to exclude recent recreational drug use 
prior to their enrolment in the study. For the tiagabine challenge study participants’ 
baseline anxiety and depression symptoms were assessed using the Beck 
Depression Inventory (BDI) (Beck et al., 1961) and the Spielberger Trait Anxiety 
Inventory (STAI) (Spielberger et al., 1970). Verbal and visuospatial memory was 
assessed using the logical memory subtest of the Wechsler Memory Scale 
(Wechsler, 1981) and the Rey-Osterrieth Complex Figure Test (Shin et al., 2006), 
respectively. All participants provided written informed consent to take part in the 
study which was approved both by the Hammersmith Research Ethics Committee 
and the Administration of Radioactive Substances Advisory Committee, UK. 
  
Tiagabine challenge study participants underwent two [11C]Ro15-4513 PET scans 
using a double-blind placebo-controlled protocol with at least one week between 
scans. These participants received an oral administration of either 15 mg tiagabine 
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or placebo ninety minutes before each scan so that peak plasma concentrations 
were highest while the participant was in the scanner. The effects of tiagabine 
administration on sedation, agitation, disorientation and ‘alcohol like drug effect’ were 
rated by investigators using ten point Likert scales. Test-retest participants 
completed two [11C]Ro15-4513 PET scans.  
 
[11C]Ro15-4513 PET imaging  
All PET scans were acquired using an ECAT HR+ 962 scanner (CTI/Siemens) with 
an axial field of view of 15.5cm. A 10 minute transmission scan was performed prior 
to each emission scan to measure tissue attenuation in two dimensional mode. Each 
participant received a fast intravenous bolus injection of 479.6MBq ±25.6 [11C]Ro15 
4513 through an intravenous cannula sited in the dominant antecubital fossa vein. 
Twenty four dynamic frames (1x30, 4x15, 4x60, 2x150, 10x300, 3x600 s) of data 
were acquired in 3D mode over 90 min and produced images containing 63 
contiguous slices. Arterial blood sampling was used to produce a metabolite-
corrected plasma input function as described previously (Lingford-Hughes et al., 
2002).  
MR Imaging 
All participants underwent a structural T1 MRI scan for co-registration purposes. MRI 
scans were acquired using a 1.5T scanner for tiagabine challenge participants (1.5 
Eclipse system, Marconi Medical Systems, Cleveland, OH, USA; TR=30 ms, 
TE=3ms, flip angle=30º, NSA=1, voxel dimensions 0.98x1.6x1.6mm3) and a 3T 
scanner for test-retest participants (3T Intera Philips Medical Systems; TR=9.6ms, 
TE=4.6ms, flip angle=8 º, NSA=1, voxel dimensions 0.94x0.94x1.2mm3). 
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[11C]Ro15-4513 PET image analysis 
All dynamic scans were corrected for head movement using frame by frame (FBF) 
realignment (Montgomery et al., 2006). This procedure was applied to all frames to 
generate a FBF corrected dynamic image, which was then analysed using an 
automated region of interest (ROI) analysis. FBF corrected reconstructed [11C]Ro15-
4513 images were analysed using Analyze AVW version 9.0 (Biomedical Imaging 
Resource, Mayo Clinic, Rochester, MN), Matlab 6, 6.5 and SPM5 (available via 
http://www.fil.ion.ucl.ac.uk/spm/). In line with our hypothesis that tiagabine 
administration would reduce synaptic GABA-BZR α1-subtype binding, we chose 
brain regions with high levels of [11C]Ro15-4513 binding (the nucleus accumbens, 
hippocampus, parahippocampal gyrus, amygdala and anterior cingulate gyrus) 
where change in synaptic GABA-BZR α1-subtype binding would be most evident. 
These regions of interest (ROIs) are also of major interest in a number of 
neuropsychiatric disorders. ROIs were placed on the [11C]Ro15-4513 images using a 
maximum probability map based on 30 participants, which defined 83 regions 
(Gousias et al., 2008; Hammers et al., 2003). Each structural MRI image was rigid-
body co-registered to the weighted summed counts image. The co-registered MRI 
was normalised to stereotaxic space using bias-corrected segmentation in SPM5 
(Ashburner and Friston, 2005). This normalisation was reversed to warp the 
maximum probability map to the co-registered structural MRI and the PET dynamic 
image. Goodness-of-fit was checked visually prior to regional sampling using object 
maps in the ROI tool in Analyze 9.0. Sampling regions of interest in each dynamic 
frame enabled the collection of time-activity curves (TACs) for each ROI. 
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[11C]Ro15-4513 specific volume of distribution (described here as VS) values were 
generated using spectral analysis. Spectral analysis is the only analysis method 
currently available that allows isolation of specific GABA-BZR α1 and α5 subtype 
receptor signals from [11C]Ro15-4513 PET images. We did not use compartmental 
modelling as this does not allow for the identification of specific α1 and α5 subtype 
binding and no appropriate reference region for each subtype exists (Myers et al., 
2012). Spectral analysis (Cunningham and Jones, 1993; Turkheimer et al., 1994) is 
a basis function technique, used to convolve the plasma input function with first order 
poly-exponentials, to fit regional TAC data, assuming system linearity and time-
invariance. The “spectrum” of dissociation rates, each represented by one or several 
closely related peaks, that effect the shape of the TAC can be divided into ranges 
that represent the different compartments of [11C]Ro15-4513 binding (Myers et al., 
2012). The range of decay values was 0.0030- 0.040 s-1 for the α1 subtype binding 
site and 0.00063-0.003 s-1 for the α5 subtype binding site. α1 and α5 subtype 
[11C]Ro15-4513 distribution volumes were calculated by summing the peak heights 
within the prescribed band (Myers et al., 2012). Spectral analysis was also used to 
calculate [11C]Ro15-4513 plasma clearance (K1) by summing the peak height across 
the total range of the spectrum, not including the fast peaks representing blood 
volume. 
Statistical Analysis 
Scan data and demographics were assessed using two-tailed t-tests. For the 
tiagabine challenge dataset, decreases in α1-specific VS values in a prori ROIs were 
assessed using a one-tailed paired t-test, given our hypothesis that a decrease in 
α1-specific [11C]Ro15-4513 binding would occur in these regions after tiagabine 
administration. Changes in α5-specific VS values in these areas after tiagabine 
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administration were assessed using two-tailed paired t-tests. Change in overall brain 
α1- and α5-specific [11C]Ro15-4513 binding after tiagabine administration was 
assessed using a two-way repeated measures ANOVA.   
For the test-retest dataset, α1- and α5-specific [11C]Ro15-4513 reliability was 
calculated using an intra-class correlation coefficient (ICC) based on a two way 
mixed effect model (Egerton et al., 2010; Shrout and Fleiss, 1979) where ICC values 
approaching +1 indicate that variance is largely due to between rather than within-
subject variation (Egerton et al., 2010). Reproducibility was calculated as the 
percentage test-retest difference (%VAR) (Egerton et al., 2010): ((retest value-test 
value)/0.5(test value+retest value)) x 100. All statistical analyses were performed 
using SPSS 20.0 (SPSS, Chicago, Illinois, USA) and all values are expressed as 
mean (SD). Power calculations were performed using GPower 3.0 (Faul et al., 
2007).  
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Results 
Tiagabine behavioural effects 
The mean tiagabine dose administered to tiagabine challenge participants was 
0.18±0.02 mg/kg. Tiagabine was generally well tolerated, although one participant 
became symptomatically hypotensive for around an hour at the end of an imaging 
session. Tiagabine administration produced increases in ‘alcohol like drug effect’ 
(mean±SD placebo and tiagabine scores: 1.2±0.9, 3.9±1.6; p=0.002), disorientation 
(mean±SD placebo and tiagabine scores: 1.2±0.6, 2.3±0.9; p=0.009), and sedation 
(mean±SD placebo and tiagabine scores: 1.6±1.4, 2.6±1.6; p=0.09), but had no 
effect on agitation (mean±SD placebo and tiagabine scores: 1.2±0.6, 1.2±0.6; 
p=1.0). These effects are similar to those from our previous studies where the main 
behavioural effects of 15mg tiagabine were described as ‘feeling of intoxication', 
‘dizziness', and ‘drug effect is like alcohol' (Muthukumaraswamy et al., 2013; 
Muthukumaraswamy et al., 2012).  
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Figure 1: Representative example of a [11C]Ro15-4513 PET image from which α1- 
and α5-subtype specific GABA-BZR receptor binding is derived (average parametric 
total VT map warped into MNI space from 5 healthy participants). Coronal view is 
displayed upper left, sagittal view is displayed upper right, axial view is displayed 
lower left and the colour bar, displayed lower right, indicates extent of total VT 
binding. 
 
[11C]Ro15-4513 PET imaging 
A representative example of a [11C]Ro15-4513 PET image, from which α1- and α5-
subtype specific GABA-BZR receptor binding is derived, is shown in Figure 1. The 
mean duration between tiagabine and placebo scans was 47.9±35.3 days, and the 
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mean duration between test-retest scans was 16.2±5.1 days. Duration between 
scans was not significantly different between the tiagabine and test-retest cohorts 
(p=0.12). Whole brain K1 values or K1 values from any of the ROI’s studied were not 
significantly different across treatment conditions for the tiagabine challenge study 
(all p values> 0.05). [11C]Ro15-4513 dose injected or Ro15-4513 mass injected also 
was not significantly different across treatment conditions (all p values> 0.05). 
 
α1-subtype tiagabine challenge results 
Tiagabine administration was associated with reductions in synaptic α1-subtype 
[11C]Ro15-4513 binding in all a priori ROI regions studied (see Table 1 and Figure 2). 
Mean α1-subtype [11C]Ro15-4513 VS was significantly reduced by 61% in the 
amygdala, 51% in the anterior cingulate gyrus, 39% in the hippocampus and 29% in 
the parahippocampal gyrus (all p values<0.05). α1-subtype VS was reduced by 54% 
at a trend significance level in the nucleus accumbens (p=0.06). Further exploratory 
post hoc analysis found that tiagabine administration was associated with a 12% 
reduction in whole brain α1-subtype [11C]Ro15-4513 binding (mean±SD whole brain 
placebo and tiagabine α1-subtype VS: 1.67±0.39, 1.44±0.56; p<0.0001). Figure 3 
shows overall [11C]Ro15-4513 spectra, divided into α1 and α5 frequency bands, 
during the placebo and tiagabine condition.  
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Figure 2: Change in α1-subtype [11C]Ro15-4513 binding after tiagabine 
administration in the nucleus accumbens (A), anterior cingulate gyrus (B), 
hippocampus (C), parahippocampal gyrus (D), and amygdala (E).  
 
 
Figure 3: [11C]Ro15-4513 spectra displayed as a sum of peaks from all regions of the 
brain in all individuals, with bands to show α1 and α5 subtype frequencies. Total 
summed peak height (s-1) is plotted against  frequency (s-1) on a logarithmic scale 
for ease of interpretation. There is a discernable reduction in curve integral in the 
prescribed α1 band associated with tiagabine administration.  
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α5-subtype tiagabine challenge results 
Tiagabine administration was associated with a significant increase of 23% in extra-
synaptic α5-subtype [11C]Ro15-4513 binding in the anterior cingulate gyrus and a 
25% trend level increase in the hippocampus (p=0.06) (see Table 1 and Figure 4). 
There were no significant changes in α5-subtype [11C]Ro15-4513 binding in the 
nucleus accumbens, parahippocampal gyrus or amygdala after tiagabine 
administration (all p values>0.1). Post hoc analysis indicated that tiagabine 
administration was associated with a 12% increase in whole brain α5-subtype 
[11C]Ro15-4513 binding (mean±SD whole brain placebo and tiagabine α5-subtype 
VS: 4.0±0.66, 4.36±0.80; p<0.0001). 
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Figure 4: Change in α5-subtype [11C]Ro15-4513 binding after tiagabine 
administration in the nucleus accumbens (A), anterior cingulate gyrus (B), 
hippocampus (C), parahippocampal gyrus (D), and amygdala (E).  
 
Correlations with memory performance and behavioural response 
Given the suggested role of the hippocampal GABA-BZR in learning and memory in 
both healthy controls (Collinson et al., 2002; Crestani et al., 2002) and alcohol 
dependent populations (Lingford-Hughes et al., 2012), we explored whether changes 
in hippocampal α1- and α5-subtype binding after tiagabine administration correlated 
with baseline visuospatial memory or verbal memory performance. Better 
visuospatial memory performance, reflected by smaller percentage decreases in 
delayed recall ROCFT visuospatial scores compared to copy scores, was associated 
at a trend significance level with greater percentage increases in hippocampal α5-
subtype binding after tiagabine administration (r=0.54, p=0.08). However, poorer 
visuospatial memory performance, reflected by larger percentage decreases in 
delayed recall ROCFT visuospatial scores compared to copy scores, was associated 
at a trend significance level with greater percentage decreases in hippocampal α1-
subtype binding after tiagabine administration (rho=0.53, p=0.10). No correlations 
were found between Wechsler Memory Scale verbal memory scores and changes in 
hippocampal α1- or α5-subtype binding (p values>0.05). Tiagabine subjective 
behavioural effects did not correlate with percentage change in either α1- or α5-
subtype [11C]Ro15-4513 binding in any of the ROI’s studied (p>0.05, correcting for 
multiple comparisons). 
 
Paul Stokes et al.  
22 
 
α1- and α5-subtype test-retest reliability and reproducibility 
α1-subtype [11C]Ro15-4513  binding reliability was excellent in the anterior cingulate 
gyrus (ICC>0.8), fair in the amygdala and parahippocampal gyrus (ICC>0.6) but poor 
in the nucleus accumbens and hippocampus (ICC<0.4) (see Table 2). α5-subtype 
reliability was excellent in the amygdala, anterior cingulate gyrus, nucleus 
accumbens, amygdala and parahippocampal gyrus (ICC>0.8) and fair in the 
hippocampus (ICC<0.6). Test-retest variability ranged between 17-38% for the α1-
subtype and 0-22% for the α5-subtype. 
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Discussion 
 
The main finding of our study is that synaptic α1-subtype [11C]Ro15-4513 binding is 
sensitive to increases in endogenous GABA produced by a tiagabine challenge. We 
found that tiagabine administration resulted in significant reductions in α1-subtype 
[11C]Ro15-4513 binding in the a priori regions of the anterior cingulate gyrus, 
amygdala, hippocampus, parahippocampal gyrus, and a reduction at a trend 
significance level in the nucleus accumbens. Additionally, we found significant global 
reductions in synaptic α1-subtype [11C]Ro15-4513 binding throughout the brain. 
Reductions in α1-subtype binding after tiagabine administration ranged in magnitude 
from 61% in the amygdala to 29% in the parahippocampal gyrus and were greater 
than test-retest variability for every a priori region studied which suggests that they 
did not arise as a result of chance observations. Moreover, none of these reductions 
were accompanied by a significant change in regional plasma clearance K1, which 
indicates that they are not a consequence of altered blood flow or ligand delivery. No 
significant relationships between cognitive measures and changes in [11C]Ro15-4513  
binding were found. 
 
This is the first time to our knowledge that reductions in synaptic α1-subtype GABA-
BZR PET tracer binding have been reported in humans after an acute GABA 
pharmacological challenge. Our findings concord with those of an autoradiographic 
study in primates where reductions in [11C]Ro15-4513 binding were reported after an 
increase in brain GABA levels (Onoe et al., 1996). They are also consistent with our 
a priori hypothesis that an increase in synaptic GABA levels, following tiagabine 
blockade of GAT1, would reduce the affinity and thus the binding of the inverse 
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agonist [11C]Ro15-4513 at synaptic α1-subtype GABA-BZR’s. Our findings suggest 
that the “GABA shift”, well described in-vitro (Braestrup et al., 1982; Onoe et al., 
1996; Tallman et al., 1978), is measurable in humans in vivo. They also suggest that 
[11C]Ro15-4513 binding at α1-subtype GABA-BZR’s is sensitive to changes in phasic 
synaptic GABA neurotransmission. 
 
Previous human neurochemical imaging studies using the GABA-BZR antagonist 
ligand [11C]flumazenil have reported alterations in overall GABA-BZR binding after 
administration of agents which increase extracellular GABA levels. Weber and 
colleagues found a trend level increase in [11C]flumazenil binding after acute 
administration of the irreversible GABA transaminase inhibitor vigabatrin (Weber et 
al., 1999). More recently, Frankle and colleagues found that acute administration of 
16 mg tiagabine increased cortical and limbic [11C]flumazenil binding (Frankle et al., 
2009) and that an acute tiagabine dose of 0.25mg/kg (17.5mg tiabagine for 70kg 
participants) was required to produce significant increases in [11C]flumazenil binding 
in the association cortex, sensory cortex and limbic regions (Frankle et al., 2012). 
Given that the affinity of GABA-BZR’s antagonists are reported not to be altered by 
increases in GABA levels in vitro (Braestrup et al., 1982) these findings would 
suggest that [11C]flumazenil is acting as a weak agonist in vivo. This is consistent 
with other in vivo studies where flumazenil appears to behave as a partial agonist 
(Higgitt et al., 1986; Miller et al., 1988) with a positive shift. Whether flumazenil is a 
partial agonist or antagonist, there is no current way of quantifying separate synaptic 
and extrasynaptic GABA-BZR binding from the [11C]flumazenil signal and so one 
cannot know whether changes in binding are a reflection of altered GABA levels 
predominantly within the synapse. The findings from this present study extends the 
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human GABA-BZR neurochemical imaging literature by demonstrating that α1-
specific binding is not only identifiable with [11C]Ro15-4513 PET but that it is also 
sensitive to increases in limbic synaptic GABA levels.  
 
We also found that tiagabine administration significantly increased overall brain 
extrasynaptic α5-subtype [11C]Ro15-4513 binding, however significant increases in 
regional binding were only found in the anterior cingulate and at a trend level in the 
hippocampus but not in the other three regions studied. The increase in α5-subtype 
binding we found is entirely consistent with the compartmental arrangement of 
[11C]Ro15-4513 binding. The reduced affinity of the α1-subtype after tiagabine 
administration, with ensuing reduced α1-subtype binding, results in an increase of 
the concentration of the free tracer in the brain. Hence the amount of tracer 
amenable to bind to the α5-subtype will increase resulting in an apparent increased 
affinity of the α5-subtype. The change in apparent affinity due to relative changes in 
the free tracer in tissue has been alternatively defined as increases in “reaction 
volume” by Delforge and colleagues (Delforge et al., 1996). 
 
Our findings indicate that increases in limbic synaptic GABA levels are detectable in 
the living human brain using [11C]Ro15-4513 PET. However, we would suggest that 
there are some constraints for using this technique in detecting differences between 
clinical populations. The test-retest results indicate that the α1-specific signal has 
relatively high test-retest variability (17-38%) with good reliability in the amygdala, 
parahippocampal gyrus and anterior cingulate gyrus, but poor reliability in the 
hippocampus and nucleus accumbens. Although the test-retest reliability estimates 
may have been affected by the small number of participants who completed this arm 
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of the study (n=4), relatively high variability in the α1-specific signal is likely to be a 
consequence of extracting a comparatively small α1-specific component from the 
[11C]Ro15-4513 PET signal. These test-retest reliability estimates do not preclude 
comparisons in clinical populations but may limit the brain regions where change can 
be reliably detected. Other factors such as the expression of GAT1 and GAT3 
uptake mechanisms may also add to the variability in the [11C]Ro15-4513 α1-specific 
signal. A potential way of reducing variability and improving the tiagabine related α1-
specific signal could be restrict analyses to regions of good reliability and to use a 
higher oral dose of tiagabine. We used a fixed oral dose of 15 mg tiagabine, 
equivalent to a mean dose of 0.18 mg/kg, which is less than the 0.25 mg/kg 
tiagabine doses reported by Frankle and colleagues as required to produce 
significant increases in [11C]flumazenil binding (Frankle et al., 2012). However as 
several of our participants reported feeling markedly drowsy after receiving 15mg 
tiagabine, and as other studies have suggested that tiagabine has the potential to 
induce stupor (Azar et al., 2013; Hamandi et al., 2014), we would suggest that any 
increases in tiagabine dose should be made cautiously.  
 
Although our results require replication and refinement, they have potentially 
important implications for the investigation of the human GABA-BZR system both in 
healthy and neuropsychiatric populations. They are particularly relevant for studying 
how alterations in synaptic GABA levels impact upon normal cognitive processes 
subserved by the limbic system such as salience, reward, emotional learning and 
memory; and to explore how increases in synaptic GABA levels differ in disorders 
where these processes may be abnormal such as anxiety disorders, affective 
disorders, schizophrenia, addiction and autism. Finally, our findings are also relevant 
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for the assessment of new treatments designed to increase limbic synaptic GABA 
levels in neuropsychiatric disorders.  
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